Skip to main content
. Author manuscript; available in PMC: 2015 Jan 3.
Published in final edited form as: Nature. 2014 May 28;511(7507):90–93. doi: 10.1038/nature13283

Figure 2. Gli1 status underpins resistance.

Figure 2

A. Gli1 mRNA levels before treatment(BT), at best response(Resp) and EOT for ribavirin-treated patients/healthy volunteers. B. Gli1 mRNA (right) and UGT1A protein (left) for patients treated with Ara-C- therapies at relapse(R)/diagnosis(D). C–D. Effects of Gli1-overexpression on drug sensitivity: ribavirin(20 uM), Ara-C(200 nM, clinically achievable7). E. siRNA to Gli1 restores drug sensitivity. siLuc, non-specific control RNA. A–B. RNA results were normalized to ubiquitin. All panels: Means+/−SD (error bars). Experiments were completed in triplicate at least three independent times. ** p-value<0.01, *** p-value<0.001 (Student’s t-test). Figure 4A–C shows corresponding westerns. Actin, tubulin and GADPH provide loading controls.